Evidence map›Paper›PMID 36396448›Full record

Observational studyNeurology(R) neuroimmunology & neuroinflammation2023

CD59 Expression in Skeletal Muscles and Its Role in Myasthenia Gravis.

Kazuo Iwasa, Yutaka Furukawa, Hiroaki Yoshikawa, Masahito Yamada, Kenjiro Ono

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Neurology(R) neuroimmunology & neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Kazuo IwasaFrom the Department of Health and Medical Sciences (K.I.), Ishikawa Prefectural Nursing University; Department of Neurology (K.I., Y.F., M.Y., K.O.), Kanazawa University Graduate School of Medical Science; Department of Neurology (Y.F.), National Hospital Organization Kanazawa Medical Center; Health Service Center (H.Y.), Kanazawa University; and Department of Neurology (M.Y.), Kudanzaka Hospital. kk.iwasa.2nd@gmail.com.
Yutaka FurukawaFrom the Department of Health and Medical Sciences (K.I.), Ishikawa Prefectural Nursing University; Department of Neurology (K.I., Y.F., M.Y., K.O.), Kanazawa University Graduate School of Medical Science; Department of Neurology (Y.F.), National Hospital Organization Kanazawa Medical Center; Health Service Center (H.Y.), Kanazawa University; and Department of Neurology (M.Y.), Kudanzaka Hospital.
Hiroaki YoshikawaFrom the Department of Health and Medical Sciences (K.I.), Ishikawa Prefectural Nursing University; Department of Neurology (K.I., Y.F., M.Y., K.O.), Kanazawa University Graduate School of Medical Science; Department of Neurology (Y.F.), National Hospital Organization Kanazawa Medical Center; Health Service Center (H.Y.), Kanazawa University; and Department of Neurology (M.Y.), Kudanzaka Hospital.
Masahito YamadaFrom the Department of Health and Medical Sciences (K.I.), Ishikawa Prefectural Nursing University; Department of Neurology (K.I., Y.F., M.Y., K.O.), Kanazawa University Graduate School of Medical Science; Department of Neurology (Y.F.), National Hospital Organization Kanazawa Medical Center; Health Service Center (H.Y.), Kanazawa University; and Department of Neurology (M.Y.), Kudanzaka Hospital.
Kenjiro OnoFrom the Department of Health and Medical Sciences (K.I.), Ishikawa Prefectural Nursing University; Department of Neurology (K.I., Y.F., M.Y., K.O.), Kanazawa University Graduate School of Medical Science; Department of Neurology (Y.F.), National Hospital Organization Kanazawa Medical Center; Health Service Center (H.Y.), Kanazawa University; and Department of Neurology (M.Y.), Kudanzaka Hospital.
Ishikawa Prefectural Nursing University · JPKanazawa University · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesComplement regulatory proteins at the neuromuscular junction (NMJ) could offer protection against complement-mediated damage in myasthenia gravis (MG). However, there is limited information on their expression at the human NMJ. Thus, this study aimed at investigating the expression of the cluster of differentiation 59 (CD59) at the NMJ of human muscle specimens and demonstrating the overexpression of

methodsIn this observational study, muscle specimens from 16 patients with MG (9 and 7 patients with and without thymoma, respectively) and 6 nonmyopathy control patients were examined. Immunohistochemical stains, Western blot analysis, and quantitative real-time reverse transcription PCR were used to evaluate the CD59 expression.

resultsA strong localized expression of CD59 was observed at the NMJ in both patients with and without MG. Moreover, the CD59/glyceraldehyde-3-phosphate dehydrogenase protein ratio in patients with MG was significantly higher than that in the nonmyopathy controls (MG; n = 16, median 0.16, interquartile range (IQR) 0.08-0.26 and nonmyopathy controls; n = 6, median 0.03, IQR 0.02-0.11, DISCUSSION: CD59, which acts as a complement regulator, may protect the NMJ from complement attack. Our findings could provide a basis for further research that investigates the underlying pathogenesis in MG and the immunomodulating interactions of the muscle cells.

Indexed as

Myasthenia Gravis, Autoimmune, ExperimentalThymus NeoplasmsActivities of Daily LivingAnimalsCD59 AntigensComplement System ProteinsHumansMuscle, SkeletalRNA, MessengerCD59 AntigensCD59 protein, humanComplement System ProteinsRNA, Messenger

Identifiers

PMID36396448
PMCPMC9747141
OpenAlexW4309510070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.